The evolving role of avotermin in scar prevention
Expert Review of Dermatology,

Nauta A et al. – Avotermin is a novel human recombinant TGF–beta 3 protein that has been studied both in vitro and in vivo for its antiscarring properties. This article evaluates a recently published Phase II clinical trial focused on the role of avotermin as a prophylactically administered, scar–reducing biologic agent for the treatment of human incisional wounds.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Dermatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Dermatology Articles

Indexed Journals in Dermatology: American Journal of Clinical Dermatology, Contact Dermatitis, Dermatologic Surgerymore